Mani Foroohar
Stock Analyst at Leerink Partners
(2.22)
# 2,719
Out of 4,896 analysts
164
Total ratings
48.31%
Success rate
n/a
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mani Foroohar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCKT Rocket Pharmaceuticals | Downgrades: Market Perform | $37 → $8 | $2.96 | +170.27% | 11 | May 28, 2025 | |
| LXEO Lexeo Therapeutics | Maintains: Outperform | $19 → $18 | $4.47 | +302.68% | 3 | Mar 24, 2025 | |
| RXRX Recursion Pharmaceuticals | Maintains: Market Perform | $7 → $6 | $5.28 | +13.64% | 8 | Feb 28, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Outperform | $31 → $27 | $4.28 | +530.84% | 9 | Jan 13, 2025 | |
| NGNE Neurogene | Maintains: Outperform | $45 → $72 | $21.43 | +235.98% | 2 | Nov 12, 2024 | |
| CAMP Camp4 Therapeutics | Initiates: Outperform | $17 | $1.50 | +1,033.33% | 1 | Nov 5, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $47 → $49 | $52.66 | -6.95% | 11 | Oct 17, 2024 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $47 → $46 | $46.47 | -1.01% | 15 | Oct 17, 2024 | |
| WVE Wave Life Sciences | Maintains: Outperform | $20 → $22 | $7.70 | +185.71% | 6 | Oct 16, 2024 | |
| IONS Ionis Pharmaceuticals | Upgrades: Outperform | $53 → $62 | $41.73 | +48.57% | 15 | Jul 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $12.71 | +2.28% | 1 | Jul 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $21.01 | +38.03% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $165 → $230 | $18.17 | +1,165.82% | 1 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $12 → $4 | $5.46 | -26.74% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $8.68 | - | 10 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $31 | $3.31 | +836.56% | 1 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $0.68 | +924.59% | 1 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $40 | $18.31 | +118.46% | 12 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $111 → $93 | $33.64 | +176.46% | 17 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $86 → $84 | $11.54 | +628.22% | 4 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $6 → $7 | $2.88 | +143.06% | 4 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $77 | $21.16 | +263.89% | 2 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $144 → $143 | $314.94 | -54.59% | 11 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $5 → $6 | $5.74 | +4.53% | 5 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $76 | $56.80 | +33.80% | 1 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $1.63 | +1,985.89% | 4 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $50 → $20 | $2.54 | +687.40% | 6 | Jul 23, 2021 |
Rocket Pharmaceuticals
May 28, 2025
Downgrades: Market Perform
Price Target: $37 → $8
Current: $2.96
Upside: +170.27%
Lexeo Therapeutics
Mar 24, 2025
Maintains: Outperform
Price Target: $19 → $18
Current: $4.47
Upside: +302.68%
Recursion Pharmaceuticals
Feb 28, 2025
Maintains: Market Perform
Price Target: $7 → $6
Current: $5.28
Upside: +13.64%
4D Molecular Therapeutics
Jan 13, 2025
Maintains: Outperform
Price Target: $31 → $27
Current: $4.28
Upside: +530.84%
Neurogene
Nov 12, 2024
Maintains: Outperform
Price Target: $45 → $72
Current: $21.43
Upside: +235.98%
Camp4 Therapeutics
Nov 5, 2024
Initiates: Outperform
Price Target: $17
Current: $1.50
Upside: +1,033.33%
Mirum Pharmaceuticals
Oct 17, 2024
Maintains: Outperform
Price Target: $47 → $49
Current: $52.66
Upside: -6.95%
BridgeBio Pharma
Oct 17, 2024
Maintains: Outperform
Price Target: $47 → $46
Current: $46.47
Upside: -1.01%
Wave Life Sciences
Oct 16, 2024
Maintains: Outperform
Price Target: $20 → $22
Current: $7.70
Upside: +185.71%
Ionis Pharmaceuticals
Jul 24, 2024
Upgrades: Outperform
Price Target: $53 → $62
Current: $41.73
Upside: +48.57%
Jul 22, 2024
Initiates: Outperform
Price Target: $13
Current: $12.71
Upside: +2.28%
Jul 2, 2024
Initiates: Outperform
Price Target: $29
Current: $21.01
Upside: +38.03%
Jun 24, 2024
Maintains: Outperform
Price Target: $165 → $230
Current: $18.17
Upside: +1,165.82%
Apr 25, 2024
Downgrades: Market Perform
Price Target: $12 → $4
Current: $5.46
Upside: -26.74%
Mar 6, 2024
Upgrades: Outperform
Price Target: n/a
Current: $8.68
Upside: -
Feb 20, 2024
Initiates: Outperform
Price Target: $31
Current: $3.31
Upside: +836.56%
Nov 30, 2023
Initiates: Outperform
Price Target: $7
Current: $0.68
Upside: +924.59%
May 12, 2023
Downgrades: Market Perform
Price Target: $40
Current: $18.31
Upside: +118.46%
Feb 24, 2023
Downgrades: Underperform
Price Target: $111 → $93
Current: $33.64
Upside: +176.46%
Jan 23, 2023
Maintains: Outperform
Price Target: $86 → $84
Current: $11.54
Upside: +628.22%
Jan 23, 2023
Maintains: Market Perform
Price Target: $6 → $7
Current: $2.88
Upside: +143.06%
Jan 23, 2023
Maintains: Outperform
Price Target: $81 → $77
Current: $21.16
Upside: +263.89%
Jan 23, 2023
Maintains: Market Perform
Price Target: $144 → $143
Current: $314.94
Upside: -54.59%
Nov 14, 2022
Maintains: Market Perform
Price Target: $5 → $6
Current: $5.74
Upside: +4.53%
Nov 7, 2022
Maintains: Outperform
Price Target: $75 → $76
Current: $56.80
Upside: +33.80%
May 12, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $1.63
Upside: +1,985.89%
Jul 23, 2021
Maintains: Market Perform
Price Target: $50 → $20
Current: $2.54
Upside: +687.40%